30 June 2026—Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO) has deployed a further RMB600.00 million of idle cash into principal-guaranteed structured deposits, splitting the funds between China Zheshang Bank (CZB) and Bank of China (BOC). The new placements elevate the company’s outstanding wealth-management balance to RMB1.49 billion.

Key transactions • CZB Structured Deposit V: SKB BIO committed RMB200.00 million to a 90-day principal-protected product starting 2 July 2026 and maturing 30 September 2026. The annualised floating return is set at 1.00 %, 2.00 % or 2.30 %, tied to movements in the EUR/USD exchange rate. Early termination is available only to CZB. • BOC Structured Deposit II: An additional RMB400.00 million was placed in a 99-day principal-protected product commencing 2 July 2026 and expiring 9 October 2026. The product offers an annualised floating return of 0.60 % or 1.90 %, linked to the GBP/USD spot rate. Neither party can terminate early except under force majeure or material regulatory change.

Outstanding positions • CZB: RMB790.00 million across four deposits (RMB100.00 million, RMB190.00 million, RMB300.00 million, RMB200.00 million). • BOC: RMB700.00 million across two deposits (RMB300.00 million, RMB400.00 million). Combined wealth-management exposure totals RMB1.49 billion.

Regulatory classification The size of the outstanding wealth-management products at each bank exceeds 5 % but is below 25 % of the applicable percentage ratios under Hong Kong Listing Rules, classifying both the CZB and BOC subscriptions as discloseable transactions subject to reporting and announcement, but not shareholder approval.

Funding source and rationale SKB BIO financed the subscriptions with idle internal funds; proceeds from prior equity offerings were not used. Management cites the short-term, principal-protected nature and higher yields relative to standard bank deposits as reasons for the allocation, viewing the terms as fair and beneficial to shareholders.